RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer

Core Insights - Revolution Medicines (RVMD) shares fell 17% following a report that Merck (MRK) is no longer pursuing the acquisition of the company due to a disagreement over the buyout price [2][3][7] - The potential acquisition discussions may resume or attract new bidders, as both companies have not commented on the situation [3][7] - Merck was previously reported to be in talks to acquire RVMD for up to $32 billion, with a valuation range of approximately $28 billion to $32 billion being considered [4] Company Overview - Revolution Medicines is focused on developing novel drugs targeting the active, GTP-bound form of RAS proteins, referred to as RAS(ON) [5] - The lead candidate, daraxonrasib, is an investigational oral RAS(ON) multi-selective inhibitor aimed at treating various forms of cancer, including metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) [8][9] - RVMD is also developing other mutant-selective inhibitors, elironrasib and zoldonrasib, for specific RAS-bearing cancer cells [10] Pipeline Progress - Daraxonrasib is currently in late-stage studies, with data readouts expected from a phase III PDAC study in 2026 and additional phase III studies for first-line metastatic PDAC and NSCLC anticipated to begin later this year [9] - The RAS(ON) inhibitors are designed to overcome resistance mechanisms that limit the efficacy of first-generation RAS inhibitors available on the market [11] Market Performance - Over the past six months, RVMD shares have increased by 162.4%, significantly outperforming the industry average rise of 21.6% [6] - Revolution Medicines currently holds a Zacks Rank of 3 (Hold), while Alkermes (ALKS) is ranked 1 (Strong Buy) with a 26.6% increase in shares over the same period [12]